Psych CASC / OSCE · Old age psychiatry — psychopharmacology
Explain safer prescribing and antipsychotic risks to family — CASC communication station
MRCPsych/FRANZCP-style communication station: explain geriatric psychotropic safety, Beers-type caution, antipsychotic mortality/stroke risk, deprescribing, and when medicines may still be used.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes active time after reading. You are the psychiatry registrar reviewing residential care medications with the resident's daughter. [1]
Candidate instructions. Explain in plain language why long-term risperidone and night temazepam are being reviewed; summarise mortality/stroke concerns with antipsychotics in dementia without causing panic; outline non-drug approaches for calling out; describe a supervised taper and what happens if severe aggression returns; check understanding. Examiner plays the daughter. [1][2][3]
Candidate scenario
Mrs L, 84, has moderate Alzheimer disease, two falls in three months, and calls out mainly at personal care times. She has been on risperidone 0.5 mg twice daily for 7 months without a documented review, and temazepam 10 mg most nights. Pain has not been systematically assessed. You plan gradual reduction of both agents, a pain and constipation review, staff ABC strategies, and a written plan to restart a low-dose antipsychotic only if severe aggression with risk of harm returns. The daughter fears both "taking away the only thing that helps" and "poisoning Mum with black-box drugs." [1][2][5]
Marking domains
- Empathy, structure, and agenda-setting with the daughter's dual fears
- Accurate plain-language explanation of antipsychotic risks in dementia and sedative fall risk
- Clear deprescribing plan with monitoring and restart threshold (not abandonment)
- Non-drug care and pain assessment as first-line for calling out
- Safety-netting and shared decision-making / teach-back [1][3][4]
Reveal assessor key
Open. Thank her for coming; name both worries (relapse of behaviour vs drug harm). Agree shared goal: comfort, safety, and fewer falls. [3]
Explain risks without jargon. Antipsychotics can help severe aggression or distressing psychosis a little for some people, but studies show a higher risk of death and stroke or stroke-like events in people with dementia compared with placebo — that is why medicines regulators warn against open-ended use. Sleeping tablets like temazepam increase confusion and falls in older people and are generally not good long-term options.[1][4]
Explain the plan. We are not abandoning care. Calling out often means pain, constipation, fear during washing, or a noisy environment — we will assess and treat those and train staff approaches. Because Mum has been stable enough for months, we will reduce risperidone slowly while watching carefully; some people do need the medicine again if dangerous aggression returns, and we would then use the lowest dose for the shortest time with a clear review date. Temazepam will also be reduced with sleep hygiene supports.[2][5]
Close. Written plan for the facility, your contact for early review if behaviour escalates, falls precautions, and teach-back of the black-box concept in her own words. [1][3]
References
- [1]Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 2005.PMID 16234500
- [2]Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) PLoS Med, 2008.PMID 18384230
- [3]By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc, 2023.PMID 37139824
- [4]Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, 2005.PMID 16284208
- [5]Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease N Engl J Med, 2012.PMID 23075176